Article Text

Download PDFPDF

5PSQ-148 Pharmacovigilance and clinical pharmacy applied to medical devices: should cancer patients be informed about their medical devices?
  1. N Nchinech,
  2. M El Harrak,
  3. B El Ouadghiri,
  4. Y Tadlaoui,
  5. Y Bousliman,
  6. J Lamsaouri,
  7. S Makram
  1. Mohammed V Military Training Hospital, Pharmacy, Rabat, Morocco


Background At our university hospital, the number of cancer patients treated by injectable chemotherapic drugs is increasing. Currently, patients need to be increasingly integrated in their own care and participate in the reporting of adverse reactions. Admittedly, under-reporting of adverse reactions related to medical devices remains a major barrier to evaluate materiovigilance in our institution. As a result, it seems important to regularly provide patients with information on their medical devices used for the administration of injectable chemotherapeutics (MD-Chemo).

Purpose To evaluate the interest in informing patients about MD-Chemo by means of a knowledge assessment questionnaire, and to explain how this can help to promote spontaneous reporting on materiovigilance by cancer patients.

Material and methods This is an observational study of 2 months, carried out at the Functional Unit of Management of Products with Particular Status (UFGPSP) of our pharmacy department during dispensing of chemotherapic drugs to cancer patients by means a questionnaire including nine topics.

Results We were able to carry out 111 interviews wherein interviewed patients showed a low level of knowledge on most of the items discussed. Seven patients did not know the medical devices they were using, and 84 had implantable ports. Among MD-Chemo carriers, 106 patients (95.5%) wished to benefit from additional information concerning their route of administration. Sixty-three patients did not know if there were precautions to take with their medical device, while 105 (94.7%) did not know the signs of a device-related infection. Adverse medical devices’ reactions reports issued by cancer patients were non-existent. This situation made it possible to target the missing information that led to the under-reporting.

Conclusion Currently, a series of participatory pharmaceutical interviews are conducted to ensure the best sharing information necessary to ensure compliance and, above all, a good quality of life. In addition, recent integration of adverse reaction reporting into the day-to-day activities of UFGPSP pharmacists, is a good way to increase the number of submitted reports.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.